Medicines360

Jul 17, 2020

Medicines360 Appoints Rolf Jansen as Vice President of Development and Manufacturing

Oct 28, 2019

FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs

May 06, 2019

Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.

Dec 10, 2018

Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Confirms Efficacy, Safety, and Tolerability Through Five Years

Oct 16, 2018

FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

Sep 06, 2018

Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Aug 20, 2018

Medicines360 and Direct Relief Partner to Expand Access for U.S. Women

May 07, 2018

Medicines360, WCG, and Population Services International Announce Launch of AVIBELA(TM) Hormonal Intrauterine System in Madagascar

Apr 30, 2018

Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study

Feb 22, 2018

FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg